PharmaCyte Biotech (PMCB) Assets Average (2016 - 2026)
PharmaCyte Biotech (PMCB) has disclosed Assets Average for 16 consecutive years, with $55.9 million as the latest value for Q1 2026.
- Quarterly Assets Average rose 13.06% to $55.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $55.9 million through Jan 2026, up 13.06% year-over-year, with the annual reading at $57.5 million for FY2025, 13.6% down from the prior year.
- Assets Average for Q1 2026 was $55.9 million at PharmaCyte Biotech, up from $50.5 million in the prior quarter.
- The five-year high for Assets Average was $92.1 million in Q1 2022, with the low at $49.5 million in Q1 2025.
- Average Assets Average over 5 years is $70.2 million, with a median of $75.1 million recorded in 2024.
- The sharpest move saw Assets Average skyrocketed 1167.73% in 2022, then crashed 34.15% in 2025.
- Over 5 years, Assets Average stood at $84.9 million in 2022, then dropped by 6.47% to $79.4 million in 2023, then decreased by 21.08% to $62.6 million in 2024, then decreased by 19.32% to $50.5 million in 2025, then rose by 10.65% to $55.9 million in 2026.
- According to Business Quant data, Assets Average over the past three periods came in at $55.9 million, $50.5 million, and $50.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.